Cargando…
OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
INTRODUCTION: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare autosomal recessive disease characterized by deficiency of cortisol and oftentimes aldosterone, with elevated adrenocorticotropic hormone (ACTH) and steroid precursors that are then shunted...
Autores principales: | Auchus, Richard, Chan, Jean, Farber, Robert, Fechner, Patricia, Giri, Nagdeep, Nokoff, Natalie, Roberts, Eiry, Sarafoglou, Kyriakie, Sturgeon, Julia, Vogiatzi, Maria, Newfield, Ron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625506/ http://dx.doi.org/10.1210/jendso/bvac150.1281 |
Ejemplares similares
-
OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study
por: Auchus, Richard J, et al.
Publicado: (2020) -
Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia
por: Newfield, Ron S, et al.
Publicado: (2023) -
Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency
por: He, Xin, et al.
Publicado: (2021) -
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
por: Auchus, Richard J, et al.
Publicado: (2021) -
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
por: Sarafoglou, Kyriakie, et al.
Publicado: (2021)